119 results about "Fatty acid-binding protein" patented technology

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to the use of biomarkers, either individually or in combinations with one another to rule in or out diseases of the aorta and its branches, most particularly aortic aneurysm and / or aortic dissection, and for risk stratification in such conditions. Preferred markers include one or more of creatine kinase-BB (CK-BB), creatine kinase-MB (CK-MB), acidic calponin, basic calponin, B-type natriuretic peptide (BNP), NT-proBNP, proBNP, BNP79-108, BNP3-108, caldesmon, caspase-3, D-dimer, soluble elastin fragments, endothelial cell-selective adhesion molecule (ESAM), fibrillin-1, heart-type fatty acid binding protein, MMP-9, myeloperoxidase, myoglobin, smooth muscle myosin, smooth muscle myosin heavy chain, TIMP-1, free cardiac troponin I, complexed cardiac troponin I, free and complexed cardiac troponin I, free cardiac troponin T, complexed cardiac troponin T, and free and complexed cardiac troponin T, and preferred assays are configured to detect these markers.

A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and / or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce developmental defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs—unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs—unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentacnoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient; increase the expression of brain lipid binding proteins (BLBPs) in the patient; improve at least one parameter of the mechanism of action of brain lipid binding proteins in the patient; overcome a deficiency of DHA in central nervous system (CNS) structures and improve the resulting function thereof; increase the incorporation of functional DHA and other PUFAs into the phospholipid membranes of glial cells and neurons in the patient; increase the level of Reelin and / or improve the activity of Reelin in the patient; and / or improve at least one symptom of a disease or condition associated with Reelin deficiency or dysfunction.

The invention relates to a medical diagnostic reagent, in particular to a quick detection reagent for the early diagnosis of acute myocardial infarction and a test strip. The invention provides a double-index united detection reagent containing a specific antibody resisting a human heart-type fatty acid binding protein H-FABP and a human cardiac troponin cTnI. The invention also provides a colloidal gold labeling immunological chromatographic test strip containing the specific antibody resisting the H-FABP and the cTnI, which is used for quickly detecting the acute myocardial infarction. The double-index united detection reagent can carry out early diagnosis on a patient having the acute myocardial infarction, can also prevent the missed diagnosis of a patient having long-time chronic myocardial infarction with mild symptoms and better solves the influence caused by a difference existing in the detection time. The colloidal gold labeling immunological chromatographic test strip provides a quick, convenient, cheap and practical detection tool for the early diagnosis of the acute myocardial infarction, is hopefully used for hospitals at all levels and can also be used for the self monitoring of the patient.

The present invention provides a method for screening or identifying therapeutic or prophylactic agents for renal diseases, which comprises assaying a test substance for the activity of up-regulating the expression of fatty acid-binding protein (FABP), and novel mouse proximal renal tubular epithelial cell lines useful therein. The present invention also provides therapeutic or prophylactic agents for renal diseases comprising, as an active ingredient, an agent having activity of up-regulating FABP expression; agents for up-regulating the expression of FABP, and for treating or preventing renal diseases, which comprise a compound having activity of peroxisome proliferator-activated receptor (PPAR) agonist or carnitine palmitoyltransferase (CPT) inhibitor or the like.

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

Methods of determining levels of unbound metabolites are disclosed. Probes derived from fatty acid binding protein muteins are described that bind preferentially to a number of unbound metabolites including oleate, stearate, linoleate, palmitate, arachidonate and unconjugated bilirubin. A profile for a patient is determined using one or more of the described probes. The profile is useful in diagnosis of disease, particularly myocardial infarction, non-alcoholic fatty liver disease (NAFLD), diabetes, stroke, sepsis and neonatal jaundice. The responses of multiple probes to a test sample are used to classify the degree of acute coronary syndrome by comparison to multi-probe profiles generated from unstable angina, non ST elevation myocardial infarction, and ST elevation myocardial infarction.

A recombinant nucleic acid is provided having an avian promoter. One embodiment of the present invention contemplates the use of a gut-specific promoter, wherein a promoter can be the chicken intestinal fatty acid binding protein promoter region. A method for making a transgenic bird is also disclosed by transfecting a bird with a vector comprising a recombinant nucleic acid comprising a chicken intestinal fatty acid binding protein promoter region operably linked to a heterologous nucleic acid expressing a desired polypeptide to be expressed in the gut tissue of an avian.

The invention provides a compound and application of the compound and the pharmaceutically acceptable salt thereof or a stereo isomer or a prodrug molecule thereof in preparing a medicament for treating or preventing metabolic diseases, wherein the compound has the structural characteristic of a general expression I and is used as a novel fat cell type fatty acid binding protein FABP inhibitor. The compound having the structural characteristic of the general expression I can provide a new selection for the clinical prevention and treatment of the following diseases: 1. type II diabetes, 2. hyperglycemia, 3. hypoglycemia tolerance, 4. insulin resistance, 5. adiposity, 6. lipid turbulence, 7. blood-lipoid imbalance, 8. hyperlipaemia, 9. hypertriglyceridemia, 10. hypercholesterolemia, 11. low high-density protein level, 12. overhigh low-density protein level, 13. atherosclerosis and secondary diseases thereof, 14. hemadostenosis, 15. abdominal obesity, 16. a metabolic syndrome and 17. fatty liver.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)

A method is described for the early detection of stroke which uses a reagent which includes a fluorescently modified fatty acid binding protein. A fluorescence difference is noted between the bound and unbound condition. Elevated levels of unbound free fatty acids from blood are used as indicators of stroke.

The physiological regulation of intake, growth and energy partitioning in animals is under the control of multiple genes, which may be important candidates for unraveling the genetic variation in economically relevant traits in beef production. The present invention relates to the identification of single nucleotide polymorphisms (SNPs) within the bovine genes encoding fatty acid binding proteins and their associations with economically relevant traits in beef production. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable meat quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field locations.

Method for examining kidney disease, which comprises detecting fatty acid binding protein derived from kidney tissues, which is present in specimen collected from mammal excluding Rodents. By the present method, it is possible to obtain test results, which may be very important information for diagnosis or prognosis of kidney disease that has been very difficult in the past. Based on test results obtained by the present method, it may be possible to select a suitable method for treatment of kidney disease with taking into consideration risks such as the prognosis, etc. Besides, the present method can be applied to, in addition to the kidney disease samples, urine samples as well, so that the examination procedure can be simple and efficient.

The present invention provides a method of determining toxicity to the heart of an anthracycline-type anticancer chemotherapeutic agent such as adriamycin etc., which comprises detecting human H-FABP (Human Heart-type Fatty Acid-Binding Protein) in the blood separated from human, a reagent therefor, a kit therefor and the like.

The invention discloses a method, system and chip test paper for parallel detection on various cardiac markers. The chip test paper is used for detecting a part or all of the cardiac markers including cTNI (cardiac troponin I), cTNT (cardiac troponin T), MYO (myoglobin), CK-MB (isoenzymeof creatine kinase containing M and B subunits), BNP (B-type natriuretic peptide), CRP (C-reactive protein) and FABP (fatty acid-binding protein); the chip test paper comprises a first membrane and a second membrane; a ligand An of each marker is arranged on the first membrane, and a ligand Bn coupled with a signal marker is absorbed on the second membrane; and a detected material forming sandwich detection together with the ligands An and Bn is added from a sampling hole, then under the acting force of percolation or other factors, the detected material moves to be combined with the ligands An and Bn respectively to form a composite array of the first membrane-the ligand An-the detected material-the ligand Bn-the signal marker, which is fixed on the first membrane, the composite array and a capture fiber membrane are assembled simultaneously, and a detection hole is reserved. The method, the system and the chip test paper provided by the invention can be used for detecting the various cardiac markers simultaneously and quantitatively; moreover, the detection sensitivity can be improved, and the detection time is saved.

The invention discloses a targeting vector and a reconstituted cell for the Cas9-mediated site-specific integration of FABP4 (adipose fatty acid-binding protein) gene and MSTN (myostatin) gene point mutation. The invention utilizes an electroporation method to co-transfect a Cas9 eukaryotic expression vector and a targeting vector targeting the MSTN gene to Luxi bovine fetal fibroblasts, consequently, gene targeting for the Luxi bovine fetal fibroblasts is realized, and bovine fetal fibroblasts with FABP4 gene and MSTN gene point mutation knocked in the MSTN site are obtained. By Junction of PCR (Polymerase Chain Reaction) screening and verification, targeted positive cloned cells are obtained. The positive cloned cells as donor cells are transplanted into denucleated bovine oocytes, so that a transgenic cloned embryo can be obtained, and thereby a solid foundation is laid for the rapid and efficient development of high-quality new genetically modified beef varieties.

The invention provides infant formula milk powder rich in milk fat globule membrane protein and phospholipid. By adding alpha-lactalbumin, milk fat globule membrane and a physiological activator, suchas bifidobacterium animalis Bb-12, milk fat globule membrane lipids and protein, N-acetylneuraminic acid (sialic acid), SN-2 structure lipid, human milk oligosaccharides (HMOs) and human milk oligose(HMO). By simultaneously adjusting the using amount ratio of all the components, especially sphingomyelin, gangliosides, the milk fat globule membrane protein, the human milk oligosaccharides, the human milk oligose, adiponectin and lysozyme, and the proportion between mucin, xanthine oxidoreductase, mucin 15, CD 36, butyrophilin, adipose differentiation-related protein and fatty acid binding proteins, the content of the active ingredients in the milk powder is closer to the content of active ingredients in human milk, the constitution of the infant formula milk powder is optimized, and the formula milk powder obtained by using the method is closer to the human milk.

The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.

The broiler breeding process features the selection of parents to be hybridized with the intramuscular fat content of breast chicken or leg chicken as main characteristic while considering also the growth speed and egg laying amount. In the same time, the individuals are supplementarily molecule mark selected early based on the genotype of inosinic acid molecular mark of fatty acid-binding protein. The method of the present invention can breed excellent broiler variety with powerful marketing competitive power and makes it possible for famous local Chinese chicken variety to enter international market.

Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

The invention belongs to the technical field of immunoassay analysis and particularly provides an enzymatic chemiluminescence immunoassay method for a human heart-type fatty acid binding protein. The method comprises the steps of forming solid phase-antibody-antigen-enzyme labelled secondary antibody immune sandwich complexes and detecting the immune sandwich complexes with the method of chemiluminescence. The invention also provides an enzymatic chemiluminescence immunoassay reagent kit for the human heart-type fatty acid binding protein. The detection method and the detection reagent kit are suitable for detecting and analyzing the human heart-type fatty acid binding protein and have the advantages of large detection range, high sensitivity and high specificity.

Provided are methods for the detection and diagnosis of Hypothyroidism. The methods are based on the discovery that altered levels of selected analytes in sample fluid, typically blood samples, of patients are supportive of a diagnosis of Hypothyroidism. At least twenty-four new biomarkers for hypothyroidism are thus disclosed (singly or in any combination), Thyroid Stimulating Hormone, Interleukin-12p40, Tumor Necrosis Factor Alpha, Tissue Factor, Interleukin-15, Insulin, Immunoglobulin E, Growth Stimulating Hormone, Calcitonin, Prostate-Specific Antigen, Interleukin-4, Granulocyte Macrophage Colony Stimulating Factor, Matrix Metalloproteinase 9, Lymphotactin, Fatty Acid Binding Protein, Alpha Fetoprotein, Alpha-2 Macroglobulin, Serum Glutamic Oxaloacetic Transaminase, Matrix Metalloproteinase 3, Cancer Antigen 125, Mumps Antibody, Double Stranded DNA Antibody, Proliferating Cell Nuclear Antigen Antibody, Smith Antibody, or Herpes Simplex Virus 1 Glycoprotein D Antibody. Altogether the concentrations of one or more of these analytes, as well as Thyroid Stimulating Hormone, or any combination thereof, provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from Hypothyroidism. Kits containing reagents to assist in the analysis of fluid samples are also described.

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

The invention discloses a fatty acid interference-resistant anti-human heart-type fatty acid binding protein monoclonal antibody and application thereof. A hybridoma cell strain FP1 capable of stably secreting the fatty acid interference-resistant anti-human heart-type fatty acid binding protein monoclonal antibody is collected with the collection number of CCTCC NO: C2016199. Through measurement, the monoclonal antibody has the titer of 1: 10<6> and the affinity of 1*10<-13>M and binding of fatty acid to H-FABP protein does not affect the affinity. An H-FABP diagnostic kit prepared on the basis of the monoclonal antibody has very high sensitivity of 0.2 ng / ml, and can resist interference of fatty acids in blood to a detection result. After adoption of the H-FABP monoclonal antibody, a high-specificity and high-accuracy detection kit for early diagnosis of acute myocardial infarction can be developed, and a key reference is provided for early diagnosis of myocardial injury.

The invention discloses an L-FABP rapid detection reagent. The L-FABP rapid detection reagent comprises a substrate and a cover plate covering the substrate, wherein a sample feeding region, a reaction region, a detection region and a waste liquid region are sequentially machined on the substrate; each of the sample feeding region, the reaction region, the detection region and the waste liquid region is composed of a micro-fluid channel; the sample feeding region is used for storing a polyester film for filtering a biological sample; a dry fluorescent microsphere marked antibody covers the reaction region; the dry fluorescent microsphere marked antibody comprises a fluorescent microsphere marked L-FABP polyclonal antibody and a fluorescent microsphere marked goat-anti-mouse immune globulin (IgG) antibody; a detection line and a control line cover the detection region; the L-FABP polyclonal antibody covers the detection line; the mouse IgG antibody covers the control line; and the waste liquid region is composed of the micro-fluid channel with a capillary action. The L-FABP rapid detection reagent disclosed by the invention has the advantages of convenience in operation, rapidness in detection, high sensitivity, good accuracy and the like; and a reagent production process is simple and convenient, pollution to the environment is not caused in the production process and the cost is low.

The invention discloses an expression vector for soluble epidermal growth factor fusion protein and application thereof. The upper stream of the cloning zone of the expression vector contains a coding sequence for human free fatty acid binding protein (FABP6) while the lower stream is a coding sequence for a human epidermal growth factor; a flexible linker coding sequence is located between the coding regions of the two genes; and the amino terminal of FABP6 contains a His-Tag tag protein coding sequence. The expression vector for the soluble epidermal growth factor fusion protein has the characteristics that 1) a ratio of soluble protein to inclusion body protein is greater than 50%; and 2) target protein can be easily obtained in virtue of histidine tag (His-Tag) affinity purification.